Lanean...
Signatures of immune reprogramming in anti-CD52 therapy of MS: markers for risk stratification and treatment response
BACKGROUND: Multiple sclerosis is one of the most prevalent neurological diseases in young adults affecting over 2 million people worldwide. Alemtuzumab is a highly effective therapy in relapsing remitting MS. Alemtuzumab is a monoclonal CD52 antibody that proved its efficacy against an active compa...
Gorde:
| Argitaratua izan da: | Neurol Res Pract |
|---|---|
| Egile Nagusiak: | , , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
BioMed Central
2019
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7650051/ https://ncbi.nlm.nih.gov/pubmed/33324905 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s42466-019-0045-x |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|